{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T08:52:16Z","timestamp":1777107136453,"version":"3.51.4"},"reference-count":115,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Reviews"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.blre.2021.100831","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T12:21:02Z","timestamp":1618575662000},"page":"100831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Novel agents for the treatment of lymphomas during pregnancy: A comprehensive literature review"],"prefix":"10.1016","volume":"49","author":[{"given":"E.","family":"Luttwak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Gurevich-Shapiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Azem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lishner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Klieger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Herishanu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Perry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Avivi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Supplement 1","key":"10.1016\/j.blre.2021.100831_bb0005","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-113836","article-title":"A phase II study of sequential pembrolizumab (PEM) followed by AVD for frontline treatment of classical Hodgkin Lymphoma (CHL): Quantifying response following PEM monotherapy with FDG-PET-derived metabolic tumor volume and total lesion glycolysis","volume":"132","author":"Savas","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.blre.2021.100831_bb0010","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.blre.2021.100831_bb0015","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1470-2045(19)30091-9","article-title":"Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b\u20132 study","volume":"20","author":"Tilly","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.blre.2021.100831_bb0020","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1200\/OP.20.00077","article-title":"Multidisciplinary Management of Cancer during Pregnancy","volume":"16","author":"Silverstein","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.blre.2021.100831_bb0025","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3389\/fimmu.2016.00550","article-title":"The PD1: PD-L1\/2 pathway from discovery to clinical implementation","volume":"7","author":"Bardhan","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2021.100831_bb0030","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/s10147-016-1036-3","article-title":"Continuing dilemmas in the management of lymphoma during pregnancy: review of a 10-point case-based questionnaire","volume":"22","author":"Amit","year":"2017","journal-title":"Int J Clin Oncol"},{"issue":"5","key":"10.1016\/j.blre.2021.100831_bb0035","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JCO.2015.62.4445","article-title":"Hematologic malignancies in pregnancy: management guidelines from an international consensus meeting","volume":"34","author":"Lishner","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.blre.2021.100831_bb0040","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1200\/JCO.2008.17.4110","article-title":"Cause-specific survival for women diagnosed with cancer during pregnancy or lactation: a registry-based cohort study","volume":"27","author":"Stensheim","year":"2009","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.blre.2021.100831_bb0045","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061356","article-title":"Frequency of pregnancy-associated cancer: A systematic review of population-based studies","volume":"12","author":"Dalmartello","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.blre.2021.100831_bb0050","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(17)30677-0","article-title":"Cancer incidence and mortality among young adults aged 20\u201339 years worldwide in 2012: a population-based study","volume":"18","author":"Fidler","year":"2017","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.blre.2021.100831_bb0055","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/jog.12597","article-title":"Incidence and outcomes of women with non-Hodgkin\u2019s lymphoma in pregnancy: a population-based study on 7.9 million births","volume":"41","author":"El-Messidi","year":"2015","journal-title":"J Obstet Gynaecol Res"},{"issue":"9815","key":"10.1016\/j.blre.2021.100831_bb0060","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0140-6736(11)61348-2","article-title":"Haematological cancers in pregnancy","volume":"379","author":"Brenner","year":"2012","journal-title":"Lancet."},{"issue":"2","key":"10.1016\/j.blre.2021.100831_bb0065","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1001\/jama.2015.7120","article-title":"Noninvasive prenatal testing and incidental detection of occult maternal malignancies","volume":"314","author":"Bianchi","year":"2015","journal-title":"JAMA - J Am Med Assoc"},{"issue":"Suppl4","key":"10.1016\/j.blre.2021.100831_bb0070","article-title":"Hodgkin lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Eichenauer","year":"2018","journal-title":"Ann Oncol"},{"issue":"suppl_5","key":"10.1016\/j.blre.2021.100831_bb0075","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.blre.2021.100831_bb0080","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1080\/17474086.2019.1615878","article-title":"Current treatment of lymphoma in pregnancy","volume":"12","author":"Gurevich-Shapiro","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"10.1016\/j.blre.2021.100831_bb0085","article-title":"NTP monograph: developmental effects and pregnancy outcomes associated with cancer chemotherapy use during pregnancy","author":"Program","year":"2013","journal-title":"NTP Monogr"},{"issue":"18","key":"10.1016\/j.blre.2021.100831_bb0090","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1182\/blood-2014-12-613570","article-title":"Obinutuzumab plus fludarabine\/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial","volume":"125","author":"Brown","year":"2015","journal-title":"Blood."},{"issue":"10168","key":"10.1016\/j.blre.2021.100831_bb0095","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet."},{"issue":"5","key":"10.1016\/j.blre.2021.100831_bb0100","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.4049\/jimmunol.1701703","article-title":"The PI3K p110\u03b4 isoform inhibitor Idelalisib preferentially inhibits human regulatory T cell function","volume":"202","author":"Chellappa","year":"2019","journal-title":"J Immunol"},{"issue":"26","key":"10.1016\/j.blre.2021.100831_bb0105","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus Chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2021.100831_bb0110","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1056\/NEJMoa1805104","article-title":"Rituximab plus lenalidomide in advanced untreated follicular lymphoma","volume":"379","author":"Morschhauser","year":"2018","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.blre.2021.100831_bb0115","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood."},{"issue":"15_suppl","key":"10.1016\/j.blre.2021.100831_bb0120","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS7585","article-title":"ZUMA-7: A phase 3 randomized trial of axicabtagene ciloleucel (Axi-Cel) versus standard-of-care (SOC) therapy in patients with relapsed\/refractory diffuse large B cell lymphoma (R\/R DLBCL)","volume":"36","author":"Oluwole","year":"2018","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.blre.2021.100831_bb0125","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/S1470-2045(17)30696-4","article-title":"Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin\u2019s lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin study group","volume":"18","author":"Eichenauer","year":"2017","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.blre.2021.100831_bb0130","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood."},{"issue":"47","key":"10.1016\/j.blre.2021.100831_bb0135","doi-asserted-by":"crossref","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene."},{"issue":"5","key":"10.1016\/j.blre.2021.100831_bb0140","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","article-title":"Pregnancy outcomes after maternal exposure to rituximab","volume":"117","author":"Chakravarty","year":"2011","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100831_bb0145","series-title":"Rituxan [package insert]. Cambridge, MA: Genentech","year":"1997"},{"issue":"4","key":"10.1016\/j.blre.2021.100831_bb0150","first-page":"661","article-title":"Pregnancy outcomes in women with rheumatoid arthritis ever treated with rituximab","volume":"56","author":"De Cock","year":"2017","journal-title":"Rheumatology."},{"issue":"3","key":"10.1016\/j.blre.2021.100831_bb0155","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000453","article-title":"Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD","volume":"5","author":"Das","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"5","key":"10.1016\/j.blre.2021.100831_bb0160","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1080\/14740338.2017.1311321","article-title":"Treatment of multiple sclerosis during pregnancy\u2013safety considerations","volume":"16","author":"Th\u00f6ne","year":"2017","journal-title":"Expert Opin Drug Saf"},{"issue":"Suppl. 1","key":"10.1016\/j.blre.2021.100831_bb0165","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1182\/blood-2018-99-113875","article-title":"Ofatumumab is active and safe in patients with relapsed\/refractory splenic marginal zone lymphoma (SMZL): results from the interim analysis of an Italian multicenter phase 2 study (MORE trial)","volume":"132","author":"Scarfo","year":"2018","journal-title":"Blood."},{"issue":"1","key":"10.1016\/j.blre.2021.100831_bb0170","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/bjh.15768","article-title":"Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance)","volume":"185","author":"Rosenbaum","year":"2019","journal-title":"Br J Haematol"},{"issue":"22","key":"10.1016\/j.blre.2021.100831_bb0175","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell\u2013mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood."},{"issue":"12","key":"10.1016\/j.blre.2021.100831_bb0180","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.blre.2021.100831_bb0185","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.blre.2021.100831_bb0190","series-title":"Gazyva [package insert]. South San-Francisco, CA: Genentech","year":"2013"},{"issue":"1","key":"10.1016\/j.blre.2021.100831_bb0195","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11307-008-0170-3","article-title":"Radioisotopic localization of 90Yttrium-Ibritumomab tiuxetan in patients with CD20+ non-Hodgkin\u2019s lymphoma","volume":"11","author":"Jacobs","year":"2009","journal-title":"Mol Imaging Biol"},{"issue":"6","key":"10.1016\/j.blre.2021.100831_bb0200","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","article-title":"Antibody\u2013drug conjugates for cancer therapy","volume":"17","author":"Thomas","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.blre.2021.100831_bb0205","first-page":"1","article-title":"New therapies in T-cell lymphoma","volume":"1","author":"Collins","year":"2014","journal-title":"Lymphoma Chronic Lymphocytic Leuk"},{"issue":"4","key":"10.1016\/j.blre.2021.100831_bb0210","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.blre.2021.100831_bb0215","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood.2019003127","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","volume":"135","author":"Straus","year":"2020","journal-title":"Blood."},{"issue":"9980","key":"10.1016\/j.blre.2021.100831_bb0220","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet."},{"issue":"8","key":"10.1016\/j.blre.2021.100831_bb0225","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1182\/blood-2014-08-595801","article-title":"Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"125","author":"Gopal","year":"2015","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2021.100831_bb0230","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1084\/jem.183.2.669","article-title":"T cell receptor-dependent cell death of T cell hybridomas mediated by the CD30 cytoplasmic domain in association with tumor necrosis factor receptor-associated factors","volume":"183","author":"Lee","year":"1996","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.blre.2021.100831_bb0235","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/0092-8674(93)90361-S","article-title":"CD30 antigen, a marker for Hodgkin\u2019s lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF","volume":"73","author":"Smith","year":"1993","journal-title":"Cell."},{"issue":"2","key":"10.1016\/j.blre.2021.100831_bb0240","first-page":"276","article-title":"High expression of the CD30 molecule in human decidual cells","volume":"145","author":"Ito","year":"1994","journal-title":"Am J Pathol"},{"issue":"5","key":"10.1016\/j.blre.2021.100831_bb0245","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/ejh.12956","article-title":"The management of hodgkin lymphomas in pregnancies","volume":"99","author":"Moshe","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.blre.2021.100831_bb0250","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000010328","article-title":"Changes in plasma soluble CD26 and CD30 during pregnancy: markers of Th1\/Th2 balance?","volume":"50","author":"Hoshimoto","year":"2000","journal-title":"Gynecol Obstet Invest"},{"issue":"6","key":"10.1016\/j.blre.2021.100831_bb0255","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1472-6483(10)61033-4","article-title":"T cells in normal pregnancy and recurrent pregnancy loss","volume":"13","author":"Piccinni","year":"2006","journal-title":"Reprod Biomed Online"},{"key":"10.1016\/j.blre.2021.100831_bb0260","series-title":"ADCETRIS [Package Insert]; Takeda Italia, Cerano, Italy","year":"2011"},{"issue":"6","key":"10.1016\/j.blre.2021.100831_bb0265","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody\u2013drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.blre.2021.100831_bb0270","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100831_bb0275","series-title":"Polivy [package insert]. San-Francisco, CA; Genentech","year":"2019"},{"issue":"1","key":"10.1016\/j.blre.2021.100831_bb0280","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1182\/blood-2017-07-740993","article-title":"PD-1 expression and clinical PD-1 blockade in B-cell lymphomas","volume":"131","author":"Xu-Monette","year":"2018","journal-title":"Blood."},{"issue":"4","key":"10.1016\/j.blre.2021.100831_bb0285","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with Nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.blre.2021.100831_bb0290","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/eji.201646875","article-title":"Immune checkpoints and their inhibition in cancer and infectious diseases","volume":"47","author":"Dyck","year":"2017","journal-title":"Eur J Immunol"},{"issue":"4","key":"10.1016\/j.blre.2021.100831_bb0295","first-page":"203","article-title":"PD-1\u2013PD-L1 immune-checkpoint blockade in B-cell lymphomas","volume":"14","author":"Goodman","year":"2017","journal-title":"Nat Publ Gr"},{"issue":"23","key":"10.1016\/j.blre.2021.100831_bb0300","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2021.100831_bb0305","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood-2016-12-758383","article-title":"Safety and tolerability of pembrolizumab in patients with relapsed\/refractory primary mediastinal large B-cell lymphoma","volume":"130","author":"Zinzani","year":"2017","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.blre.2021.100831_bb0310","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/bdrb.21176","article-title":"An evaluation of the impact of PD-1 pathway blockade on reproductive safety of therapeutic PD-1 inhibitors","volume":"107","author":"Poulet","year":"2016","journal-title":"Birth Defects Res Part B Dev Reprod Toxicol"},{"issue":"11","key":"10.1016\/j.blre.2021.100831_bb0315","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.30642","article-title":"Immune checkpoint inhibitors in challenging populations","volume":"123","author":"Johnson","year":"2017","journal-title":"Cancer."},{"issue":"1","key":"10.1016\/j.blre.2021.100831_bb0320","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41419-018-1251-0","article-title":"Blockade of CTLA-4 and Tim-3 pathways induces fetal loss with altered cytokine profiles by decidual CD4+ T cells","volume":"10","author":"Wang","year":"2019","journal-title":"Cell Death Dis"},{"issue":"3","key":"10.1016\/j.blre.2021.100831_bb0325","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.seminoncol.2018.03.003","article-title":"Viable pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy","volume":"45","author":"Burotto","year":"2018","journal-title":"Semin Oncol"},{"issue":"4","key":"10.1016\/j.blre.2021.100831_bb0330","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/CMR.0000000000000657","article-title":"Conception and Viable Twin Pregnancy in a Patient With Metastatic Melanoma while Treated with CTLA-4 and PD-1 Checkpoint Inhibition","volume":"30","author":"Bucheit","year":"2020","journal-title":"Melanoma Res"},{"key":"10.1016\/j.blre.2021.100831_bb0335","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.ejca.2018.09.008","article-title":"Immunotherapy with ipilimumab plus nivolumab in a stage IV melanoma patient during pregnancy","volume":"104","author":"Menzer","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.blre.2021.100831_bb0340","first-page":"1","article-title":"Case report of a pregnancy during ipilimumab therapy","volume":"4","author":"Mehta","year":"2018","journal-title":"J Glob Oncol"},{"issue":"3","key":"10.1016\/j.blre.2021.100831_bb0345","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/CMR.0000000000000586","article-title":"Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature","volume":"29","author":"Xu","year":"2019","journal-title":"Melanoma Res"},{"issue":"3","key":"10.1016\/j.blre.2021.100831_bb0350","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1097\/QCO.0000000000000372","article-title":"Placental transfer of antibody and its relationship to vaccination in pregnancy","volume":"30","author":"Calvert","year":"2017","journal-title":"Curr Opin Infect Dis"},{"issue":"3","key":"10.1016\/j.blre.2021.100831_bb0355","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1053\/j.seminoncol.2018.03.005","article-title":"A comparative analysis of immune privilege in pregnancy and cancer in the context of checkpoint blockade immunotherapy","volume":"45","author":"Flint","year":"2018","journal-title":"Semin Oncol"},{"key":"10.1016\/j.blre.2021.100831_bb0360","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3389\/fimmu.2013.00371","article-title":"Antigen-specific T-cell activation independently of the MHC: chimeric antigen receptor-redirected T cells","volume":"4","author":"Chmielewski","year":"2013","journal-title":"Front Immunol"},{"key":"10.1016\/j.blre.2021.100831_bb0365","author":"U.S. Food and Drug Administration"},{"issue":"9","key":"10.1016\/j.blre.2021.100831_bb0370","first-page":"832","article-title":"CAR-T therapy is approved for mantle cell Lymphoma","volume":"324","author":"Voelker","year":"2020","journal-title":"JAMA - J Am Med Assoc"},{"issue":"Supplement 1","key":"10.1016\/j.blre.2021.100831_bb0375","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2020-134449","article-title":"Interim ANALYSIS of ZUMA-12: A phase 2 study of Axicabtagene Ciloleucel (Axi-Cel) as first-line therapy in patients (Pts) with high-risk large B cell Lymphoma (LBCL)","volume":"136","author":"Neelapu","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.blre.2021.100831_bb0385","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.blre.2021.100831_bb0390","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous Lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.blre.2021.100831_bb0395","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","article-title":"Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma","volume":"373","author":"Ruan","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.blre.2021.100831_bb0400","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1016\/S2352-3026(18)30131-5","article-title":"Lenalidomide in combination with R-CHOP (R2-CHOP) as first-line treatment of patients with high tumour burden follicular lymphoma: a single-arm, open-label, phase 2 study","volume":"5","author":"Tilly","year":"2018","journal-title":"Lancet Haematol"},{"issue":"3","key":"10.1016\/j.blre.2021.100831_bb0405","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1053\/j.seminhematol.2017.06.003","article-title":"Lenalidomide: Myelodysplastic syndromes with del (5q) and beyond","volume":"54","author":"Talati","year":"2017","journal-title":"Semin Hematol"},{"issue":"13","key":"10.1016\/j.blre.2021.100831_bb0410","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2217\/fon-2016-0130","article-title":"ROBUST: lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma","volume":"12","author":"Nowakowski","year":"2016","journal-title":"Future Oncol"},{"issue":"11","key":"10.1016\/j.blre.2021.100831_bb0415","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/s41408-018-0145-9","article-title":"Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials","volume":"8","author":"Castellino","year":"2018","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1016\/j.blre.2021.100831_bb0420","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.blre.2021.100831_bb0425","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1002\/bdrb.20115","article-title":"Evaluation of the developmental toxicity of lenalidomide in rabbits","volume":"80","author":"Christian","year":"2007","journal-title":"Birth Defects Res Part B Dev Reprod Toxicol"},{"issue":"10","key":"10.1016\/j.blre.2021.100831_bb0430","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood-2018-10-879429","article-title":"Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia","volume":"133","author":"Burger","year":"2019","journal-title":"Blood."},{"issue":"10121","key":"10.1016\/j.blre.2021.100831_bb0435","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet."},{"issue":"Supplement_1","key":"10.1016\/j.blre.2021.100831_bb0440","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-124443","article-title":"Clinical impact of Ibrutinib with R-CHOP in untreated non-GCB DLBCL Co-expressing BCL2 and MYC genes in the phase 3 phoenix trial","volume":"134","author":"Johnson","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.blre.2021.100831_bb0445","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/hon.39_2629","article-title":"ACCEPT: a phase IB\/II combination of acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for patients with diffuse large b-cell lymphoma (DLBCL)","volume":"37","author":"Cummin","year":"2019","journal-title":"Hematol Oncol"},{"issue":"17","key":"10.1016\/j.blre.2021.100831_bb0450","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1200\/JCO.2013.53.1046","article-title":"Bruton\u2019s tyrosine kinase: from X-linked agammaglobulinemia toward targeted therapy for B-cell malignancies","volume":"32","author":"Ponader","year":"2014","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.blre.2021.100831_bb0455","first-page":"483","article-title":"Ibrutinib (imbruvica): a novel targeted therapy for chronic lymphocytic leukemia","volume":"39","author":"Parmar","year":"2014","journal-title":"Pharm Ther"},{"issue":"9","key":"10.1016\/j.blre.2021.100831_bb0460","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/jth.14225","article-title":"Acquired platelet antagonism: off-target antiplatelet effects of malignancy treatment with tyrosine kinase inhibitors","volume":"16","author":"Tullemans","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"23","key":"10.1016\/j.blre.2021.100831_bb0465","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/blood.V126.23.3435.3435","article-title":"Ibrutinib treatment modulates T cell activation and polarization in immune response","volume":"126","author":"Li","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100831_bb0470","series-title":"Calquence [package insert]. Cambridge, United Kingdom: AstraZeneca","year":"2017"},{"issue":"3","key":"10.1016\/j.blre.2021.100831_bb0475","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/blood-2016-02-702761","article-title":"Idelalisib in the management of lymphoma","volume":"128","author":"Cheah","year":"2016","journal-title":"Blood."},{"issue":"7","key":"10.1016\/j.blre.2021.100831_bb0480","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1158\/1078-0432.CCR-14-2522","article-title":"FDA approval: idelalisib monotherapy for the treatment of patients with follicular lymphoma and small lymphocytic lymphoma","volume":"21","author":"Miller","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.blre.2021.100831_bb0485","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/14728214.2018.1479396","article-title":"Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin\u2019s lymphoma","volume":"23","author":"Rodgers","year":"2018","journal-title":"Expert Opin Emerg Drugs"},{"issue":"5","key":"10.1016\/j.blre.2021.100831_bb0490","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1158\/1078-0432.CCR-13-3173","article-title":"Molecular pathways: linking tumor microenvironment to epithelial\u2013mesenchymal transition in metastasis","volume":"21","author":"Jung","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.blre.2021.100831_bb0495","doi-asserted-by":"crossref","first-page":"10175","DOI":"10.1002\/jcb.28302","article-title":"Inhibition of the PI3K\/Akt signaling pathway impedes the restoration of neurological function following hypoxic-ischemic brain damage in a neonatal rabbit model","volume":"120","author":"Luo","year":"2019","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.blre.2021.100831_bb0500","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2147\/DDDT.S109325","article-title":"Development of venetoclax for therapy of lymphoid malignancies","volume":"11","author":"Zhu","year":"2017","journal-title":"Drug Des Devel Ther"},{"issue":"9","key":"10.1016\/j.blre.2021.100831_bb0505","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood-2017-04-737338","article-title":"Targeting BCL-2 in B-cell lymphomas","volume":"130","author":"Davids","year":"2017","journal-title":"Blood."},{"issue":"18","key":"10.1016\/j.blre.2021.100831_bb0510","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","article-title":"Venetoclax plus R-or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial","volume":"133","author":"Zelenetz","year":"2019","journal-title":"Blood."},{"key":"10.1016\/j.blre.2021.100831_bb0515","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.theriogenology.2017.07.045","article-title":"Bcl-2\/Bax protein and mRNA expression in yak (Bos grunniens) placentomes","volume":"104","author":"Fan","year":"2017","journal-title":"Theriogenology."},{"issue":"1","key":"10.1016\/j.blre.2021.100831_bb0520","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/cdd.2017.170","article-title":"Anti-apoptotic BCL-2 family members in development","volume":"25","author":"Opferman","year":"2018","journal-title":"Cell Death Differ"},{"issue":"8","key":"10.1016\/j.blre.2021.100831_bb0525","first-page":"476","article-title":"Pharmaceutical approval update","volume":"41","author":"Kaufman","year":"2016","journal-title":"Pharm Ther"},{"key":"10.1016\/j.blre.2021.100831_bb0530","series-title":"VENCLEXTA [package insert]; Illinois, USA: AbbVie","year":"2019"},{"issue":"1","key":"10.1016\/j.blre.2021.100831_bb0535","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/toxsci\/kfq316","article-title":"Developmental immunotoxicology assessment of rituximab in cynomolgus monkeys","volume":"119","author":"Vaidyanathan","year":"2011","journal-title":"Toxicol Sci"},{"issue":"1","key":"10.1016\/j.blre.2021.100831_bb0540","first-page":"7","article-title":"Birth outcome in women with breast cancer, cutaneous malignant melanoma, or Hodgkin\u2019s disease: a review","volume":"3","author":"Langagergaard","year":"2011","journal-title":"Clin Epidemiol"},{"issue":"11","key":"10.1016\/j.blre.2021.100831_bb0545","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1016\/S2352-3026(19)30195-4","article-title":"Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study","volume":"6","author":"Maggen","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.blre.2021.100831_bb0550","first-page":"17103","article-title":"Maternal and neonatal outcomes in 80 patients diagnosed with non-Hodgkin lymphoma during pregnancy: results from the International Network of Cancer, Infertility and Pregnancy","author":"Maggen","year":"2020","journal-title":"Br J Haematol"},{"issue":"7\u20138","key":"10.1016\/j.blre.2021.100831_bb0555","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1159\/000473880","article-title":"Chemotherapy during pregnancy: cases of hodgkin\u2019s and non-hodgkin\u2019s lymphoma, chronic myeloid leukemia, breast cancer, nasopharyngeal cancer, and choriocarcinoma","volume":"40","author":"Beksac","year":"2017","journal-title":"Oncol Res Treat"},{"issue":"32","key":"10.1016\/j.blre.2021.100831_bb0560","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1200\/JCO.2013.49.8220","article-title":"Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis","volume":"31","author":"Evens","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.blre.2021.100831_bb0565","doi-asserted-by":"crossref","first-page":"623924","DOI":"10.5402\/2011\/623924","article-title":"A systematic review and meta-analysis of regimens for peripheral T-cell lymphoma","volume":"2011","author":"Abouyabis","year":"2011","journal-title":"ISRN Hematol"},{"issue":"14","key":"10.1016\/j.blre.2021.100831_bb0570","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1158\/0008-5472.CAN-17-0082","article-title":"Venetoclax synergizes with radiotherapy for treatment of B-cell lymphomas","volume":"77","author":"O\u2019Steen","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.blre.2021.100831_bb2010","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s40425-019-0657-2","article-title":"Transgenerational transfer of gene-modified T cells","volume":"7","author":"Cosgrove","year":"2019","journal-title":"J Immunotherapy cancer"},{"issue":"16","key":"10.1016\/j.blre.2021.100831_bb2000","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2017","journal-title":"New England Journal of Medicine"}],"container-title":["Blood Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X21000370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0268960X21000370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T20:26:21Z","timestamp":1759436781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0268960X21000370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":115,"alternative-id":["S0268960X21000370"],"URL":"https:\/\/doi.org\/10.1016\/j.blre.2021.100831","relation":{},"ISSN":["0268-960X"],"issn-type":[{"value":"0268-960X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel agents for the treatment of lymphomas during pregnancy: A comprehensive literature review","name":"articletitle","label":"Article Title"},{"value":"Blood Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.blre.2021.100831","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100831"}}